Huadong Medicine announced that the company and its wholly-owned subsidiary participated in the 12th round of national centralized drug procurement. Cyclosporine soft capsules, tacrolimus capsules, and mesalazine enteric-coated tablets were tentatively selected. In 2025, the combined sales revenue of these products was approximately 2.076 billion yuan, accounting for 4.76% of total revenue. Four other products, including isavuconazole injection, were not selected. Their combined sales revenue in 2025 was approximately 4.634 billion yuan, accounting for 10.62% of total revenue, and their hospital market share is expected to decline. The company has formulated operational contingency plans to cope with procurement pressure.
Huadong Medicine Co LtdProducts not selected in national procurement will lose hospital market share, while selected products face price cuts.